外周动脉药物洗脱技术治疗外周动脉疾病的研究进展

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI:10.17925/HI.2021.15.2.73
Leonardo Marques, Silke Hopf-Jensen, Michael Preiss, Stefan Mueller-Huelsbeck
{"title":"外周动脉药物洗脱技术治疗外周动脉疾病的研究进展","authors":"Leonardo Marques,&nbsp;Silke Hopf-Jensen,&nbsp;Michael Preiss,&nbsp;Stefan Mueller-Huelsbeck","doi":"10.17925/HI.2021.15.2.73","DOIUrl":null,"url":null,"abstract":"<p><p>For the treatment of peripheral arterial disease, drug-eluting technology is a widely accepted therapeutic option, with significant reduction in intimal hyperplasia and, consequently, use of target lesion revascularization. Nevertheless, the reputation of such devices was damaged after a meta-analysis, published in December 2018, showed increased mortality in patients receiving paclitaxel-eluting devices. Although subsequent studies have failed to establish such correlation, the use of paclitaxel-eluting devices remains heavily restricted. As such, other options and drugs have been developed, for instance sirolimus. In this article we present the available data on drug-eluting technology.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524588/pdf/heart-int-15-73.pdf","citationCount":"2","resultStr":"{\"title\":\"An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease.\",\"authors\":\"Leonardo Marques,&nbsp;Silke Hopf-Jensen,&nbsp;Michael Preiss,&nbsp;Stefan Mueller-Huelsbeck\",\"doi\":\"10.17925/HI.2021.15.2.73\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>For the treatment of peripheral arterial disease, drug-eluting technology is a widely accepted therapeutic option, with significant reduction in intimal hyperplasia and, consequently, use of target lesion revascularization. Nevertheless, the reputation of such devices was damaged after a meta-analysis, published in December 2018, showed increased mortality in patients receiving paclitaxel-eluting devices. Although subsequent studies have failed to establish such correlation, the use of paclitaxel-eluting devices remains heavily restricted. As such, other options and drugs have been developed, for instance sirolimus. In this article we present the available data on drug-eluting technology.</p>\",\"PeriodicalId\":12836,\"journal\":{\"name\":\"Heart International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2021-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524588/pdf/heart-int-15-73.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/HI.2021.15.2.73\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2021.15.2.73","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 2

摘要

对于外周动脉疾病的治疗,药物洗脱技术是一种被广泛接受的治疗选择,可以显著减少内膜增生,从而使用靶病变血运重建术。然而,在2018年12月发表的一项荟萃分析显示,接受紫杉醇洗脱装置的患者死亡率增加后,这种装置的声誉受到了损害。尽管随后的研究未能建立这种相关性,紫杉醇洗脱装置的使用仍然受到严格限制。因此,已经开发了其他选择和药物,例如西罗莫司。在这篇文章中,我们介绍了药物洗脱技术的现有数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease.

For the treatment of peripheral arterial disease, drug-eluting technology is a widely accepted therapeutic option, with significant reduction in intimal hyperplasia and, consequently, use of target lesion revascularization. Nevertheless, the reputation of such devices was damaged after a meta-analysis, published in December 2018, showed increased mortality in patients receiving paclitaxel-eluting devices. Although subsequent studies have failed to establish such correlation, the use of paclitaxel-eluting devices remains heavily restricted. As such, other options and drugs have been developed, for instance sirolimus. In this article we present the available data on drug-eluting technology.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Heart International
Heart International Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.90
自引率
0.00%
发文量
9
审稿时长
7 weeks
期刊最新文献
Efficacy of Commonly Used 3D Mapping Systems in Acute Success Rates of Catheter Ablation Procedures. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Femoral Neck Osteoporosis Is Associated with a Higher Odds of Coronary Artery Disease in Indian Postmenopausal Women: A Cross-sectional Study from a Teaching Hospital in Southern India. Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies. A Comprehensive Evaluation of the NAVITOR Transcatheter Aortic Valve Replacement System.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1